Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Breast 1

Conditions

Breast Neoplasms 47Breast Neoplasms, Male 5Neoplasms 4Neoplasm Metastasis 4Carcinoma, Ovarian Epithelial 2Sarcoma 1Recurrence 1Pancreatic Neoplasms 1Pain 1Ovarian Neoplasms 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Colonic Neoplasms 1Carcinoma 1Breast Cancer Organoids 1Bilateral Breast Carcinoma 1

Interventions

pembrolizumab 8Carboplatin 6Cyclophosphamide 5veliparib 4olaparib 4Magnetic Resonance Spectroscopy 4liposomal doxorubicin 3Taxes 3Paclitaxel 3Gene Expression Profiling 3Gemcitabine 3palbociclib 2niraparib 2fludarabine 2durvalumab 2Temozolomide 2Specimen Handling 2Psychiatric Rehabilitation 2Polymerase Chain Reaction 2Oxaliplatin 2Nivolumab 2Leucovorin 2Interleukin-2 2Fulvestrant 2Fluorouracil 2Early Intervention, Educational 2Drug Therapy 2Doxorubicin 2Biopsy 2130-nm albumin-bound paclitaxel 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × ixabepilone × Breast × Clear all
NCT00182767 2016-03-10

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
45 enrolled 8 charts
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡